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Abstract: 
Aims: 
Although the role of phosphorylation of oestrogen receptor (ER) at serines 
118 (p-S118) and 167 (p-S167) have been studied, the relationship between 
p-S118, p-S167 and the tumour microenvironment in ER-positive primary 
operable ductal breast cancers have not been investigated. The aims of this 
study are to investigate (1) the relationship between p-S118/p-S167 and the 
tumour microenvironment and (2) the effect of p-S118/167 on survival and 
recurrence in ER-positive primary operable ductal breast cancers. 
 
Methods and Results: 
Patients presenting at 3 Glasgow hospitals between 1995 and 1998 with 
invasive ductal ER-positive primary breast cancers were studied (n=294). 
Immunohistochemical staining of p-S118 and p-S167 was performed and their 
association with clinico-pathological characteristics, cancer-specific survival 
(CSS) and recurrence-free interval (RFI) were examined. 
In the whole cohort, tumour size (P=<0.05) and microvessel density (P=<0.05) 
were associated with high p-S118 while increased micovessel density 
(P=<0.05), apoptosis (P=<0.05), general inflammatory infiltrate measured 
using the Klintrup-Makinen score (P=<0.05) and macrophage infiltrate 
(P=<0.05) were found to be associated with high p-S167. Only high p-S167 
was associated with shorter CSS (P=<0.005) and shorter RFI in the whole 
cohort (P=0.001) and luminal A (P=<0.05) and B tumours (P=<0.05) 
separately.  
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Conclusions: 
This study showed that both p-S118 and p-S167 were associated with several 
microenvironmental factors including increased microvessel density.  In 
particular, p-S167 was associated with reduced RFI and CSS in the whole 
cohort and RFI in luminal A and B tumours and could possibly be employed to 
predict response to kinase inhibitors.  
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Introduction 
 
Breast cancer, which accounts for 30% of new incidences of cancer in 
females, is the most common cancer in the UK. With improved treatment 
modalities, the survival rate has increased significantly with 78.4% patients 
having 10-year survival 1.  
 
Breast cancer can be categorised according to the expression of 
immunohistochemical surrogates (oestrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 1 and 2 and 
cytokeratin 5 and 6) for molecular classification. ER-positive tumours can be 
subcategorised into luminal A and B tumours; the former being associated 
with expression of PR, low proliferation markers (Ki-67), low grade and good 
outcomes but prone to late recurrences while the latter is associated with high 
proliferation markers and high grade.  
 
The treatment of ER-positive breast cancers have improved with the 
introduction of tamoxifen, a competitive inhibitor of ER, and recent reports 
show that aromatase inhibitors (e.g. letrozole), which inhibit the conversion of 
androgen to oestrogen, may be more clinically beneficial compared to 
tamoxifen in post-menopausal women 2. Patients using either drugs may 
exhibit de novo resistance or acquired resistance, leading to endocrine 
therapy failure 3. Studies showed that 90% and 30% of patients with luminal B 
and luminal A tumours respectively exhibit high recurrence scores 4, 5. In 
addition to tamoxifen and aromatase inhibitors, other therapeutic options 
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including Faslodex and LHRH agonists have been developed and are still 
under study. Thus, there is a continuing need to identify patients that are more 
likely to develop resistance and therefore provide more rigorous follow-up.  
 
The ER-Alpha (ER-α) receptor can be phosphorylated at a number of amino 
acid residues including serines 118 and 167 6, 7. There is still not a clear 
consensus on the role of phosphorylation at serines 118 (p-S118) and 167 (p-
S167) in tamoxifen resistance due to conflicting evidence. 
 
The tumour microenvironment has been shown to play an important role in 
cancer development. Studies have shown that factors including microvessel 
density, lymphovascular invasion, tumour necrosis, inflammatory infiltrates, 
tumour stromal percentage and tumour budding are important in determining 
patient’s response to therapy 8-13. However, the relationship between p-
S118/p-S167 and the tumour microenvironment has not been studied. Thus, 
the aims of the study are to investigate (1) the relationship between p-S118/p-
S167 and the tumour microenvironment and (2) the effect of p-S118/167 on 
survival and recurrence in ER-positive primary operable ductal breast 
cancers. Considering the importance of the microenvironment and ER 
phosphorylation status, we hypothesise that these factors may have to be 
considered jointly in determining recurrence risk.
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Materials and Methods: 
 
Patients 
 
Ethical approval for expression studies in human tissue samples was obtained 
from West of Scotland Research Ethics Service West of Scotland REC4 (REC 
Ref: Project Number 02/SG007(10), R and D project: RN07PA001). Although 
patient consent was not obtained, all patient details were anonymised and 
identifiers were removed. Patients included in this study were diagnosed with 
operable ER-positive breast cancers at 3 Glasgow hospitals; The Royal 
Infirmary, Stobhill Hospital, and Western Infirmary between 1995 and 1998 
(n=294) and treated with adjuvant tamoxifen. Clinico-pathological 
characteristics including age, tumour size, invasive grade in histological 
grade, histological tumour type, nodal status, lymphovascular invasion, type of 
surgery and adjuvant therapy (chemotherapy and radiotherapy) were 
retrieved from routine reports. Recurrences and cancer deaths were used as 
end points. The date and cause of death was confirmed by cross-checks with 
the Registrar General (Scotland) and the cancer registration system. 
Recurrences were defined as the date of first recurrence of breast cancer. 
Recurrence-free interval (RFI) was measured from the time of surgery until 
the date of first recurrence at any site. Breast cancer-specific survival (CSS) 
was measured from time of surgery to death due to breast cancer. Patients 
were followed up regularly after surgery. 
 
Immunohistochemistry (IHC) 
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One 0.6mm2 core from each tumour taken during surgery was placed in each 
of three separate TMA blocks (Beecher Scientific, Silver Spring, MD, USA). 
2.5μm-thick paraffin wax sections from each TMA block were mounted on 
silanised glass slides for IHC. All TMAs were available from previous studies 
and were designed in triplicates. ER, PR and HER-2 status were performed 
as described previously 14. IHC staining on TMAs was also used to assess for 
Ki-67 using Dako anti-Ki67 (1:100; monoclonal mouse anti-human, Ki-67 
antigen, clone MIB1, code M7240, DAKO, Glostrup, Denmark) with a cut-off 
of 15% 15. Tumour stromal percentage refers to the area of stroma in a single 
X10 field with tumour cells at all corners. Tumour budding refers to the 
detachment of single or cluster of five cancer cells in the stroma at the 
invasive margins of the tumour 16. 
 
The tissues were first dewax and rehydrated. For antigen retrieval, sections 
were heated in Sodium Citrate buffer at pH 6 for 1.5 minutes in a pressure 
cooker until under pressure and then for another 5 minutes once pressure 
conditions have been achieved. Following this, samples were cooled for 20 
minutes. Blocking of endogenous peroxidase was achieved by incubation of 
tissue in 3% hydrogen peroxidase for 10 minutes. Samples were incubated in 
1.5% horse serum for 30 minutes to block non-specific binding. Following this, 
the samples were incubated in the primary antibodies at 4°C overnight; p-
S118 (1:500 dilution; Cell Signalling, #2511) and p-S167 (1:200; Cell 
Signalling, #5587). The specificity of the antibodies have been shown 
previously 17, 18. Phospho-ER epitopes antigenicity have been shown to be 
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stable 19. The slides were then washed twice in TBS for 5 minutes before 
incubation in Dako EnVisionTM (K5007, Dako, Copenhagen, Denmark) before 
washing in TBS buffer again twice for 5 minutes. Diaminobenzidine (SK-4100, 
Vector Laboratories, Burlingame, CA, USA), which was used as a chromogen, 
was prepared according to manufacturer’s instructions. The slides were 
counterstained with haematoxylin, dehydrated and mounted with DPX. TMAs 
of breast cancer patients without linked clinical data were used as positive 
and negative controls for each antibody. 
 
Slide Scanning and Scoring 
 
The stained tissue microarrays were scanned using a Hamamatsu 
NanoZoomer (Welwyn Garden City, Hertfordshire, UK). SlidePath Digital 
Image Hub, version 4.0.1 (SlidePath’s Tissue IA system, Dublin, Ireland) was 
used for visualisation and automated cell counts. Scoring of tissues was 
performed by assessors blinded to clinico-pathological characteristics of 
patients. Samples were scored according to the weighted histoscore/H score 
method 20. In brief, staining intensity was graded as negative (0), weak (1), 
moderate (2) and strong (3) multiplied by the percentage of cells in each 
category resulting in a range of scores from 0 to 300. Two hundred and forty 
cores (10% of total tissue cores) were scored for nuclear p-S118 and p-S167 
by one observer (KC) and an automated tissue analysis system blinded to 
patient’s details and each other’s scores. The Interclass Correlation 
Coefficient for the observer and the automated results were 0.984 and 0.978 
for p-S118 and p-S167 respectively. Subsequently, SlidePath was used to 
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score the rest of the cores. The use of automated systems have been shown 
to be an effective alternative to manual scoring of samples 21. The mean 
score was taken as the final score for each tumour triplicate.  
 
Statistical Analysis 
SPSS version 22 (SPSS Inc., Chicago, IL, USA) was used to perform 
statistical analysis. The Kaplan-Meier method was used to estimate survival 
(CSS) and recurrence-free interval (RFI), and the log-rank test was used to 
assess differences between survival curves. The Cox-proportional hazards 
model was used for univariate and multivariate survival analysis and the 
calculation of hazard ratios (HR). Mortality up to March 2010 was included in 
the analysis and served as a censor date. The X2 test (or X2 test for trend 
where appropriate) was used to determine association between p-S118/p-
S167 with clinico-pathological data.
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Results: 
 
As shown in Table 1, the majority of patients were above 50 years of age 
(76.5%), had small (< 20cm in diameter) (66.3%), Grade I or II (80.7%) 
tumours without lymph node involvement (56.5%). Histologically, most 
patients were PR-positive (67.3%), HER2-negative (89.8%) and of the 
Luminal A subtype (64.6%). Proliferative index indicated by Ki-67 was 
predominantly low (70.1%) and the majority of tumours had significant 
inflammatory infiltrate (assessed using the Klintrup-Makinen method 22) 
(87.8%). The majority of patients were not treated with chemotherapy (71.8%) 
or radiotherapy (58.2%) but all patients received tamoxifen. Based on the 
information we have on 293 patients, the patients were on tamoxifen for a 
median duration of 5 years (IQR – 4.5 to 5.0 years) and a mean duration of 
4.69 years. As the median was used to distinguish between low and high 
expression of p-S118 and p-S167 (92.5 for p-S118 and 14 for p-S167), there 
were roughly equal numbers of tumours with high or low p-S118 and p-S167. 
Figure 1 shows the immunohistochemical staining of p-S118 and p-S167 in 
ER-positive and negative tumours. 
 
Tables 2 and 3 show the relationship between p-S118, p-S167, tumour 
microenvironmental factors and clinico-pathological characteristics. High p-
S118 was associated with tumour size (P=0.011) and microvessel density 
(P=0.023). Similarly, high p-S167 was associated with increased microvessel 
density (P=0.009), apoptotic index indicated by TUNEL (P=0.002), general 
inflammatory infiltrate (P=0.007) and CD68+ macrophage infiltrate (P=0.010). 
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p-S118 and p-S167 were strongly positively associated with each other 
(P=0.003).  
 
The patients were followed-up for a median of 70 months (IQR – 59 to 81 
months) During the follow-up period, 46 patients experienced recurrence. At 
the end of follow-up, 110 patients died and of these, 48 deaths could be 
directly attributed to their disease. Of the other deaths, 15 were due to 
malignant disease of other organs (including lung and colon cancer), 18 due 
to vascular diseases (including coronary heart disease and cerebrovascular 
disease) and 16 due to respiratory diseases (including chronic obstructive 
pulmonary disease and pneumonia). High p-S167 was associated with 
significantly shorter CSS (152 vs. 170 months; P=0.003; Figure 2B) and RFI 
(91 vs. 101 months; P=0.001; Figure 2D) compared to tumours with low p-
S167. Mean CSS (158 vs. 160 months; P=0.507; Figure 2A) and RFI (95 vs. 
95 months; 0.443; Figure 2B) were not significantly different in tumours with 
low or high expression of p-S118. When compared together, patients with 
high p-S167 were more associated with poorer CSS and RFI compared to p-
S118 (Figure 3). 
 
Sub-group analyses were performed based on tumour subtypes – luminal A 
and B. High p-S118 was associated with tumour size (P=0.024), grade 
(P=0.042), microvessel density (P=0.008), general inflammatory infiltrate 
(P=0.036) and the use of chemotherapy (P=0.037) or radiotherapy (P=0.046) 
in luminal A tumours and associated with blood vessel invasion (P=0.042) in 
luminal B tumours. On the other hand, high p-S167 was associated with PR-
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positive status (P=0.032), increased microvessel density (P=0.026), apoptotic 
index indicated by TUNEL (P=0.013) and CD68+ macrophage infiltrate 
(P=0.030) in luminal A tumours (Table 4). p-S167 was not significantly 
associated with any clinico-pathological characteristics in luminal B tumours. 
 
Survival analyses showed that high p-S167 was associated with shorter RFI 
in both subtypes – Luminal A  (92 vs. 105 months; P=0.032; Figure 4A) and 
Luminal B (128 vs. 153 months: P=0.033; Figure 4B). The same association 
was seen on multivariate analysis (Table 5) – Luminal A (HR 4.441, 95% CI 
1.004-19.638, P=0.049) and B (HR 4.971, 95% CI 1.386-17.834, P=0.014). p-
S118 and p-S167 were not associated with CSS in luminal A and B tumours 
(Table 6).
 14 
Discussion 
 
Although there have been studies investigating the role of p-S118, p-S167 
and the tumour microenvironment individually in determining survival, the 
relationship between these factors have not been investigated. The present 
study observed associations between both p-S118 and p-S167 and several 
microenvironmental factors. However, only p-S167 had power in stratifying 
patients according to outcome measures, as it was associated with 
recurrence-free interval and cancer-specific survival in the full cohort and with 
recurrence-free interval in the luminal A and B tumours. This may be due to p-
S167 associating with more variables associated with the tumour 
microenvironment. 
 
The weighted histoscore/H score method was used in the present study 
although the IHC cut-off method and the Allred method is used by some 
researchers as it is widely accepted that the weighted histoscore/H score 
method could be more informative than the Allred method. McCarty et al. 
recommended that this should be the method of choice for assessing ER in 
breast tumours 23.  Since then, it has been widely adapted in the research 
field as the method of choice (although Allred is still employed clinically).  
More recently, Brouckaert et al. discussed reasons why a quantitative 
assessment of the steroid receptors in breast cancer is the preferred method 
and that we should employ a weighted histoscore/H score method rather than 
the quick score or Allred method 24.  
 
 15 
In addition, as the weighted histoscore/H score method was employed in the 
TEAM (adjuvant tamoxifen and exemestane in early breast cancer) clinical 
trial to assess ER levels and as we plan to take these investigations forward 
into this cohort, it seemed appropriate to use the same method for assessing 
phospho-ER as to what was used to assess ER and PR 21, 25. In addition to 
the evidence presented by others, we as a group are widely published in the 
area of biomarker research using the weighted histoscore/H score method 
and have been employing this method for over 10 years 20. We have 
demonstrated that it has high inter-observer reliability, can be easily converted 
to the Allred score if required and algorithms can be written for automated 
scoring. The median was used as the cut-off for low and high as it is an 
unbiased measure and is more informative than 1% or 10% as previously 
employed by others.  
 
In the present study, ER levels and phospho-ER levels were assess using 
IHC as ligand binding assays have been demonstrated to provide inaccurate 
results due to tissues inherently being a heterogenous mix of tumour and 
stromal cells. Using IHC, we can be sure that the expression status of ER and 
phospho-ER is unaffected by non-tumour cells. If ER or phospho-ER was 
assessed using ligand binding assays, results would have varied due to 
inconsistencies in tumour stromal percentage between specimens 26. 
 
Whilst we recognise the merits of examining tumour samples by a second 
technique, we believe the IHC strategy allows us to examine ER 
phosphorylation in multiple cell types (tumour and surrounding 
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microenvironment) that make up the heterogeneous sample.  In addition, the 
use of IHC allows us to assess expression in different cellular regions. 
Unfortunately, as we only had archival paraffin-embedded specimens 
available for this study, immunoblotting of the specimens could not be 
performed. In addition, it should be recognised that it is standard clinical 
practice to employ the use of IHC to assess biomarker protein expression in 
formalin-fixed, paraffin-embedded clinical specimens. IHC is the gold standard 
method used to assess expression of ER and PR in breast cancer clinical 
specimens and is utilised to inform appropriate patient treatment strategies. 
Therefore, we feel that it is appropriate to utilise this technique in the present 
study, especially as stringent antibody validation using both immunoblotting 
and IHC was employed. 
 
Due to conflicting evidence, the role of p-S118 and p-S167 in tamoxifen 
resistance remains unclear. While p-S118 has been reported to be associated 
with better prognosis, a less malignant phenotype and higher response rate to 
tamoxifen 17, 27, some studies have also shown its association with poorer 
response to endocrine therapy 28, 29. Kirkegaard et al. showed that activated 
Akt is associated with relapse and death in ER-α positive, tamoxifen-treated 
patients, thus suggesting that p-S167 may be associated with worse disease 
outcome while Yamashita et al. showed that p-S167 was predictive of 
response to endocrine therapy and longer survival after relapse 29, 30. This 
study reports that high p-S167 is associated with poor prognosis and higher 
microvessel density, apoptotic index and macrophage infiltrate, all of which 
are associated with poorer prognosis 8, 31, 32, thus supporting the association 
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of p-S167 with poorer outcomes. Given these associations, p-S167 may be 
involved with signalling pathways associated with inflammatory cytokine 
release. Future studies should focus on identifying these pathways as they 
may be useful therapeutic targets. 
 
Svensson et al. showed that high serum oestradiol levels were associated 
with high levels of extracellular CCL2 and CCL5 in vivo, inducing infiltration of 
tumour-associated macrophages 33. Similarly, the role of estradiol in the 
recruitment and activation of macrophages have also been shown in ovarian 
cancer 34. These studies support our findings that ER activation is associated 
with macrophage infiltration, both of which are associated with poorer 
prognosis. 
 
p-S167 was found to be a predictor of a shorter recurrence-free interval in 
both luminal A and B cancers and was also associated with higher 
microvessel density, apoptotic index and macrophage infiltration in luminal A 
tumours. This suggests that luminal A tumours can be further subcategorised 
into 2 groups by p-S167 status. Although patients with luminal A tumours 
have good prognosis, the difference in recurrence-free interval between 
patients with high and low expression of p-S167 was about 1 year in this 
study. Therefore, identification of these patients using p-S167 for more 
rigorous treatment may be clinically useful. Luminal B tumours have been 
known to have a more aggressive phenotype, thought to be due to the 
upregulation of HER2, leading to the upregulation of Akt and MAPK pathways. 
As p-S167 is associated with these pathways, p-S167 may be important in 
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stratifying patients with luminal B tumours. Replication of our findings in a 
larger cohort such as the TEAM trial would establish the utility of p-S167 as 
an important biomarker for stratifying patients in future clinical trials.  
 
Increasing number of patients undergo ‘switch therapy’ (a sequential switch to 
aromatase inhibitors after tamoxifen) or have extended treatments of up to 10 
years of tamoxifen or aromatase inhibition. It would be interesting to 
investigate whether these strategies have an effect on levels of p-S118 and p-
S167. However, as this was not the case for the present cohort, it was not 
possible to address this. 
 
Recently, studies have shown that recurrent ESR1 mutations within the ligand 
binding domain (LBD) in ER-positive endocrine-resistant metastatic breast 
cancer were identified at higher frequencies in patients who received multiple 
hormonal treatments, suggesting that the mutations result in increased ER 
activity and thus increased tumour growth, presenting as a clinical relapse 35, 
36. As p-S167 is associated with a shorter recurrence-free interval, it would be 
interesting to look at the relationship between p-S167 mutation and LBD 
mutations of ESR1. As LBD mutations are relatively uncommon in treatment-
naïve patients, it would be advisable to examine these mutations in patients 
who have already received multiple hormonal treatments. 
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Conclusion
 
In summary, this study showed the utility of p-S118 and p-S167 in stratifying 
patients’ risk of relapse and the relationship between p-S118 and p-S167 and 
the tumour microenvironment. As p-S167 was associated with recurrence-free 
interval and cancer-specific survival in the whole cohort and recurrence-free 
interval in luminal A and B tumours, p-S167 may be an important biomarker 
for stratifying patients in the future. 
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Tables 
Table 1: Clinico-pathological Characteristics of patients with ER-positive operable invasive ductal breast cancers (n=294) 
Clinico-pathological characteristics  Patients, n (%) 
Age (≤50/ >50 years)  69 (23.5%)/225 (76.5%) 
Size (≤20/ 21-50/ > 50mm)  195 (66.3%)/92 (31.3%)/7 (2.4%) 
Grade (I/ II/ III) 81 (27.6%)/156 (53.1%)/57 (19.4%) 
Molecular subtype (Luminal A/Luminal B/Unknown) 190 (64.6%)/87 (29.6%)/17 (5.8%) 
Involved lymph node (Negative/Positive/Unknown)  166 (56.5%)/124 (42.2%)/4 (1.4%) 
Progesterone -receptor status (PR-/PR+/Unknown)  95 (32.3%)/198 (67.3%)/1 (0.3%) 
HER2 status (HER2-/HER2+/Unknown)  264 (89.8%)/26 (8.8%)/4 (1.4%) 
Lymph vessel invasion (Absent/Present)  208 (70.7%)/86 (29.3%) 
Blood vessel invasion (Absent/Present) 263 (89.5%)/31 (10.5%) 
Microvessel Density (CD34+) (Low/Medium/High/Unknown)  100 (34.0%)/93 (31.6%)/81 (27.6%)/20 (6.8%) 
Ki-67 status (Low/High/Unknown)  206 (70.1%)/74 (25.2%)/14 (4.8%) 
Tumour necrosis (Absent/Present)  181 (61.6%)/113 (38.4%) 
TUNEL (Low/High/Unknown)  134 (45.6%)/124 (42.2%)/36 (12.2%) 
General Inflammatory Infiltrate (Low/High)  258 (87.8%)/36 (12.2%) 
Chemotherapy (Negative/Positive/Unknown) 211 (71.8%)/81 (27.6%)/2 (0.7%) 
Radiotherapy (Negative/Positive/Unknown) 171 (58.2%)/121 (41.2%)/2 (0.7%) 
Tumour CD4+ T-lymphocytic infiltrate (Low/Medium/High/Unknown)  145 (49.3%)/60 (20.4%)/81 (27.6%)/8 (2.7%) 
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Tumour CD8+ T-lymphocytic infiltrate (Low/Medium/High/Unknown)  95 (32.3%)/108 (36.7%)/83 (28.2%)/8 (2.7%) 
Tumour CD20+ B-lymphocytic infiltrate (Low/Medium/High/Unknown) 170 (57.8%)/43 (14.6%)/73 (24.8%)/8 (2.7%) 
Tumour CD138+ B-Lymphocytic infiltrate (Low/Medium/High/Unknown)  168 (57.1%)/41 (13.9%)/76 (25.9%)/9 (3.1%) 
Tumour CD68+ macrophages infiltrate (Low/Medium/High/Unknown)  72 (24.5%)/116 (39.5%)/96 (32.7%)/10 (3.4%) 
Tumour Stromal Percentage (Low/High) 194 (66.0%)/100 (34.0%) 
Tumour Budding (Low/High) 176 (59.9%)/118 (40.1%) 
p-S118 (Low/High)  154 (52.4%)/140 (47.6%) 
p-S167 (Low/High)  113 (38.4%)/181 (61.6%) 
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Table 2: The relationship between p-S118 expression and clinico-pathological characteristics of patients with invasive ER-positive primary 
operable ductal breast cancers. 
Clinico-pathological characteristics  Low p-S118 expression  High p-S118 expression p-value 
Age (≤50/ >50 years)  37/117 32/108 0.922 
Size (≤20/ 21-50/ > 50mm)  91/57/6 104/35/1 0.011 
Grade (I/ II/ III) 47/84/23 34/72/34 0.107 
Molecular subtype (Luminal A/Luminal B) 106/41 84/46 0.226 
Involved lymph node (Negative/ Positive)  82/69 84/55 0.350 
Progesterone -receptor status (PR-/PR+)  48/106 47/92 0.720 
HER2 status (HER2-/HER2+) 142/10 122/16 0.198 
Lymph vessel invasion (Absent/Present)  107/47 101/39 0.709 
Blood vessel invasion (Absent/Present) 133/21 130/10 0.105 
Microvessel Density (CD34+) (Low/Medium/High)  60/48/32 40/45/49 0.023 
Ki-67 status (Low/High)  113/36 93/38 0.434 
Tumour necrosis (Absent/Present)  90/64 91/49 0.301 
TUNEL (Low/High)  69/66 65/58 0.878 
General Inflammatory Infiltrate (Low/High)  140/14 118/22 0.121 
Chemotherapy (Negative/Positive) 103/50 108/31 0.065 
Radiotherapy (Negative/Positive) 97/56 74/65 0.101 
Tumour CD4+ T-lymphocytic infiltrate (Low/Medium/High)  80/32/36 65/28/45 0.291 
Tumour CD8+ T-lymphocytic infiltrate (Low/Medium/High)  42/60/46 53/48/37 0.198 
Tumour CD20+ B-lymphocytic infiltrate (Low/Medium/High) 86/23/39 84/20/34 0.893 
Tumour CD138+ B-Lymphocytic infiltrate (Low/Medium/High)  93/19/36 75/22/40 0.380 
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Tumour CD68+ macrophages infiltrate (Low/Medium/High)  37/64/47 35/52/49 0.659 
Tumour Stromal Percentage (Low/High) 94/60 100/40 0.079 
Tumour Budding (Low/High) 84/70 92/48 0.067 
Cancer-specific survival (months)* 158 (150-165) 160 (153-168) 0.507 
Recurrence-free interval (months)* 95 (90-100) 95 (90-100) 0.443 
p-S167 (Low/High)  72/82 41/99 0.003 
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Table 3: The relationship between p-S167 expression and clinico-pathological characteristics of patients with invasive ER-positive primary 
operable ductal breast cancers. 
Clinico-pathological characteristics  Low p-S167 expression  High p-S167 expression p-value 
Age (≤50/ >50 years)  31/82 38/143 0.260 
Size (≤20/ 21-50/ > 50mm)  78/33/2 117/59/5 0.689 
Grade (I/ II/ III) 37/60/16 44/96/41 0.112 
Molecular subtype (Luminal A/Luminal B) 77/27 113/60 0.167 
Involved lymph node (Negative/ Positive)  64/49 102/75 0.965 
Progesterone -receptor status (PR-/PR+)  39/74 56/124 0.633 
HER2 status (HER2-/HER2+)  101/10 163/16 1.000 
Lymph vessel invasion (Absent/Present)  83/30 125/56 0.421 
Blood vessel invasion (Absent/Present) 100/13 163/18 0.819 
Microvessel Density (CD34+) (Low/Medium/High)  50/31/24 50/62/57 0.009 
Ki-67 status (Low/High)  83/22 123/52 0.142 
Tumour necrosis (Absent/Present)  72/41 109/72 0.634 
TUNEL (Low/High)  60/32 74/92 0.002 
General Inflammatory Infiltrate (Low/High)  107/6 151/30 0.007 
Chemotherapy (Negative/Positive) 74/39 137/42 0.055 
Radiotherapy (Negative/Positive) 65/48 106/73 0.869 
Tumour CD4+ T-lymphocytic infiltrate (Low/Medium/High)  57/22/29 88/38/52 0.856 
Tumour CD8+ T-lymphocytic infiltrate (Low/Medium/High)  37/38/33 58/70/50 0.778 
Tumour CD20+ B-lymphocytic infiltrate (Low/Medium/High) 60/18/30 110/25/43 0.579 
Tumour CD138+ B-Lymphocytic infiltrate (Low/Medium/High)  72/13/22 96/28/54 0.082 
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Tumour CD68+ macrophages infiltrate (Low/Medium/High)  37/34/36 35/82/60 0.010 
Tumour Stromal Percentage (Low/High) 74/39 120/61 0.987 
Tumour Budding (Low/High) 66/47 110/71 0.779 
Cancer-specific survival (months)* 170 (165-175) 152 (144-160) 0.003 
Recurrence-free interval (months)* 101 (95-107) 91 (86-95) 0.001 
p-S118 (Low/High)  72/41 82/99 0.003 
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Table 4: The relationship between p-S167 expression and clinico-pathological characteristics of patients with invasive Luminal A and B ER-
positive primary operable ductal breast cancers. 
Clinico-pathological characteristics  Luminal A Luminal B 
Low p-S167 
expression  
High p-S167 
expression 
p-
value 
Low p-S167 
expression  
High p-S167 
expression 
p-
value 
Age (≤50/ >50 years)  20/57 23/90 0.464 7/20 13/47 0.872 
Size (≤20/ 21-50/ > 50mm)  55/20/2 78/32/3 0.937 15/12/0 31/27/2 0.620 
Grade (I/ II/ III) 32/42/3 35/63/15 0.057 2/13/12 5/29/26 0.987 
Involved lymph node (Negative/ Positive)  45/32 70/40 0.572 13/14 26/33 0.905 
Progesterone -receptor status (PR-/PR+)  32/45 29/84 0.032 5/22 24/36 0.085 
HER2 status (HER2-/HER2+)  77/0 113/0  17/10 44/16 0.469 
Lymph vessel invasion (Absent/Present)  58/19 88/25 0.815 17/10 29/31 0.302 
Blood vessel invasion (Absent/Present) 67/10 105/8 0.266 24/3 50/10 0.728 
Microvessel Density (CD34+) (Low/Medium/High)  37/25/12 34/41/32 0.026 9/6/11 14/21/24 0.429 
Ki-67 status (Low/High)  77/0 113/0  6/21 8/52 0.466 
Tumour necrosis (Absent/Present)  51/26 77/36 0.906 15/12 25/35 0.332 
TUNEL (Low/High)  42/24 46/61 0.013 16/8 28/29 0.229 
General Inflammatory Infiltrate (Low/High)  75/2 100/13 0.050 24/3 43/17 0.136 
Chemotherapy (Negative/Positive) 52/25 90/22 0.067 14/13 41/19 0.217 
Radiotherapy (Negative/Positive) 44/33 68/44 0.734 18/9 32/28 0.353 
Tumour CD4+ T-lymphocytic infiltrate (Low/Medium/High)  40/18/19 60/23/28 0.909 14/3/9 21/15/24 0.193 
Tumour CD8+ T-lymphocytic infiltrate (Low/Medium/High)  25/32/20 36/42/33 0.824 9/6/11 17/27/16 0.141 
Tumour CD20+ B-lymphocytic infiltrate (Low/Medium/High) 42/15/20 72/16/23 0.358 15/3/8 31/9/20 0.854 
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Tumour CD138+ B-Lymphocytic infiltrate (Low/Medium/High)  51/10/15 66/12/33 0.303 17/3/6 24/15/21 0.089 
Tumour CD68+ macrophages infiltrate (Low/Medium/High)  26/25/25 22/56/33 0.030 6/9/11 8/25/27 0.518 
Tumour Stromal Percentage (Low/High) 51/26 69/44 0.567 16/11 44/16 0.288 
Tumour Budding (Low/High) 44/33 70/43 0.608 14/13 36/24 0.633 
Cancer-specific survival (months)* 173 (167-
178) 
163 (155-
171) 
0.179 158 (143-
173) 
130 (115-
145) 
0.064 
Recurrence-free interval (months)* 105 (101-
108) 
92 (88-96) 0.032 153 (138-
168) 
128 (111-
145) 
0.033 
p-S118 (Low/High)  51/26 55/58 0.025 16/11 25/35 0.198 
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Table 5: The relationship between the clinico-pathological characteristics of patients with invasive Luminal A and B ER-positive primary 
operable ductal breast cancers and recurrence-free interval. 
Clinico-pathological 
characteristics 
Luminal A Luminal B 
Univariate   Multivariate  Univariate  Multivariate  
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Age (≤50/ >50 years)  1.971 (0.446-8.701) 0.371   0.633 (0.243-1.647) 0.349   
Size (≤20/ 21-50/ > 50mm)  1.580 (0.644-3.880) 0.318   1.083 (0.500-2.348) 0.839   
Grade (I/ II/ III) 1.869 (0.820-4.258) 0.137   1.221 (0.578-2.582) 0.600   
Involved lymph node 
(Negative/ Positive)  
1.923 (0.666-5.548) 0.227   5.330 (1.781-15.948) 0.003 4.854 (1.521-15.487) 0.008 
Progesterone -receptor status 
(PR-/PR+)  
0.751 (0.272-2.075) 0.581   0.365 (0.151-0.884) 0.026 0.369 (0.151-0.899) 0.028 
HER2 status (HER2-/HER2+)  -    1.318 (0.531-3.274) 0.552   
Lymph vessel invasion 
(Absent/Present)  
1.597 (0.571-4.462) 0.372   2.370 (0.979-5.739) 0.056   
Blood vessel invasion 
(Absent/Present) 
2.235 (0.628-7.959) 0.214   1.487 (0.496-4.458) 0.479   
Microvessel Density (CD34+) 
(Low/Medium/High)  
1.777 (0.883-3.577) 0.107   1.586 (0.888-2.832) 0.119   
Ki-67 status (Low/High)  -    1.211 (0.354-4.142) 0.760   
Tumour necrosis 
(Absent/Present)  
1.904 (0.707-5.128) 0.203   2.231 (0.865-5.756) 0.097   
TUNEL (Low/High)  0.385 (0.120-1.231) 0.108   0.659 (0.267-1.626) 0.365   
General Inflammatory Infiltrate 
(Low/High)  
0.043 (0.000-155.046) 0.451   0.483 (0.141-1.653) 0.246   
Chemotherapy 
(Negative/Positive) 
1.234 (0.425-3.584) 0.699   3.606 (1.438-9.044) 0.006 3.837 (1.469-10.023) 0.006 
Radiotherapy 
(Negative/Positive) 
0.515 (0.176-1.512) 0.227   0.877 (0.363-2.122) 0.771   
Tumour CD4+ T-lymphocytic 
infiltrate (Low/Medium/High)  
0.662 (0.338-1.297) 0.229   0.877 (0.544-1.415) 0.591   
Tumour CD8+ T-lymphocytic 
infiltrate (Low/Medium/High)  
0.904 (0.492-1.661) 0.745   0.580 (0.333-1.009) 0.054   
Tumour CD20+ B-lymphocytic 
infiltrate (Low/Medium/High) 
1.120 (0.632-1.986) 0.698   0.996 (0.627-1.584) 0.988   
Tumour CD138+ B-
Lymphocytic infiltrate 
(Low/Medium/High)  
0.824 (0.452-1.501) 0.526   1.529 (0.927-2.520) 0.096   
Tumour CD68+ macrophages 
infiltrate (Low/Medium/High)  
0.586 (0.289-1.185) 0.137   1.199 (0.644-2.233) 0.566   
Tumour Stromal Percentage 2.396 (0.890-6.449) 0.084   1.607 (0.675-3.828) 0.284   
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(Low/High) 
Tumour Budding (Low/High) 1.278 (0.471-3.472) 0.630   1.779 (0.753-4.200) 0.189   
p-S118 (Low/High)  0.678 (0.245-1.876) 0.454   0.790 (0.333-1.869) 0.591   
p-S167 (Low/High) 4.441 (1.004-19.638) 0.049 4.441 (1.004-19.638) 0.049 3.504 (1.029-11.940) 0.045 4.971 (1.386-17.834) 0.014 
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Table 6: The relationship between the clinico-pathological characteristics of patients with invasive Luminal A and B ER-positive primary 
operable ductal breast cancers and cancer-specific survival. 
 
Clinico-pathological 
characteristics 
Luminal A Luminal B 
Univariate   Multivariate  Univariate  Multivariate  
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Age (≤50/ >50 years)  2.741 (0.629-11.932) 0.179   1.375 (0.522-3.619) 0.519   
Size (≤20/ 21-50/ > 50mm)  1.652 (0.728-3.749) 0.230   2.024 (1.046-3.919) 0.036   
Grade (I/ II/ III) 1.480 (0.704-3.111) 0.301   1.305 (0.720-2.365) 0.380   
Involved lymph node 
(Negative/ Positive)  
1.814 (0.700-4.706) 0.221   3.318 (1.457-7.553) 0.004  0.056 
Progesterone -receptor status 
(PR-/PR+)  
0.462 (0.183-1.163) 0.101   0.783 (0.361-1.697) 0.535   
HER2 status (HER2-/HER2+)  -    0.917 (0.389-2.161) 0.843   
Lymph vessel invasion 
(Absent/Present)  
1.607 (0.603-4.284) 0.343   3.570 (1.566-8.138) 0.002 2.871 (1.227-6.715) 0.015 
Blood vessel invasion 
(Absent/Present) 
3.083 (1.014-9.368) 0.047  0.103 1.628 (0.660-4.017) 0.290   
Microvessel Density (CD34+) 
(Low/Medium/High)  
1.666 (0.887-3.128) 0.112   1.279  (0.808-2.023) 0.294   
Ki-67 status (Low/High)  -    1.754 (0.529-5.816) 0.358   
Tumour necrosis 
(Absent/Present)  
3.586 (1.390-9.255) 0.008 3.704 (1.434-9.568) 0.007  2.241 (1.009-4.977) 0.047  0.466 
TUNEL (Low/High)  0.649 (0.236-1.788) 0.403   0.874 (0.409-1.869) 0.728   
General Inflammatory Infiltrate 
(Low/High)  
9.943 (0.000-50.842) 0.383   0.828 (0.336-2.044) 0.683   
Chemotherapy 
(Negative/Positive) 
0.783 (0.258-2.381) 0.667   1.879 (0.895-3.944) 0.096   
Radiotherapy 
(Negative/Positive) 
0.354 (0.116-1.077) 0.067   0.949 (0.449-2.007) 0.892   
Tumour CD4+ T-lymphocytic 
infiltrate (Low/Medium/High)  
0.784 (0.435-1.414) 0.419   0.765 (0.508-1.152) 0.200   
Tumour CD8+ T-lymphocytic 
infiltrate (Low/Medium/High)  
0.811 (0.449-1.464) 0.487   0.551 (0.337-0.899) 0.017 0.580 (0.339-0.991) 0.046 
Tumour CD20+ B-lymphocytic 
infiltrate (Low/Medium/High) 
0.824 (0.456-1.490) 0.522   0.731 (0.467-1.142) 0.169   
Tumour CD138+ B-
Lymphocytic infiltrate 
(Low/Medium/High)  
1.128 (0.663-1.918) 0.657   1.259 (0.828-1.914) 0.281   
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Tumour CD68+ macrophages 
infiltrate (Low/Medium/High)  
0.841 (0.460-1.535) 0.572   1.105 (0.663-1.8430 0.702   
Tumour Stromal Percentage 
(Low/High) 
3.254 (1.258-8.419) 0.015 3.371 (1.301-8.735) 0.012  3.102 (1.458-6.600) 0.003 2.304 (1.051-5.051) 0.037 
Tumour Budding (Low/High) 2.468 (0.956-6.365) 0.062   2.592 (1.212-5.545) 0.014  0.481 
p-S118 (Low/High)  0.598 (0.224-1.595) 0.304   0.823 (0.392-1.729) 0.607   
p-S167 (Low/High) 2.001 (0.713-5.618) 0.188   2.417 (0.918-6.361) 0.074   
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